Important Facts About Alkermes – A Must-Know for Investors

By Kim Brooks • Friday, August 25 13:08 • Permanent Link

One of the losers of today's trading session was Alkermes. Shares of the Pharmaceutical company plunged -3.0%, and some investors may be wondering if its price of $26.73 would make a good entry point. Here's what you should know if you are considering this investment:

Alkermes has moved 9.0% over the last year, and the S&P 500 logged a change of 10.0%
ALKS has an average analyst rating of buy and is -27.11% away from its mean target price of $36.67 per share
Its trailing earnings per share (EPS) is $0.54
Alkermes has a trailing 12 month Price to Earnings (P/E) ratio of 49.5 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $2.13 and its forward P/E ratio is 12.5
The company has a Price to Book (P/B) ratio of 3.48 in contrast to the S&P 500's average ratio of 2.95
Alkermes is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
The company has a free cash flow of $146.74 Million, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in the fields of neuroscience and oncology in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence, and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.